Healthy
Conditions
Brief summary
The objective of this study was to investigate the influence of meloxicam on low dose aspirin induced inhibition of platelet aggregation and thromboxane B2, when meloxicam is given before aspirin.
Interventions
DRUGMeloxicam
DRUGAspirin
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male or female subjects as determined by results of screening * Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation * Age \>=18 and \<= 60 years * The Body Mass Index (BMI) ≥ 18.5 kg/m2 (square meters) and ≤ 29.9 kg/m2. * Laboratory values within a clinical normal range
Exclusion criteria
* Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram (ECG)) deviating from normal and of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * Surgery of the gastro-intestinal tract (except appendectomy) * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * History of orthostatic hypotension, fainting spells or blackouts * Chronic or relevant acute infections * History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * Intake of drugs with a long half-life (\> 24 hours) (\< 1 month prior to administration or during the trial) * Use of any drugs, which might influence the results of the trial, in particular aspirin containing drugs(\< 14 days prior to administration or during the trial) * Participation in another trial with an investigational drug (\< 1 months prior to administration (at least 10 times the relevant elimination half-life) or during trial) * Having had prescription medication 2 weeks prior to study drug administration or over the counter medication 1 week prior to study drug administration (at least 10 times the relevant elimination half-life) * Smoker (\> 10 cigarettes or 3 cigars or 3 pipes/day) * Inability to refrain from smoking on trial days * Alcohol abuse (\> 60 grams (g)/day) * Drug abuse * Blood donation or loss \> 400 mL (\< 1 month prior to administration or during the trial) * Excessive physical activities (\< 5 days prior to administration or during the trial) * Any ECG value outside of the reference range of clinical relevance including, but not limited to QTcB \> 480 ms or QRS interval \> 110 ms * History of any familial bleeding disorder * History of haemorrhagic diatheses * History of gastrointestinal ulcer, perforation or bleeding * History of bronchial asthma * Inability to comply with dietary regimen of study centre * Inability to comply with investigator's instructions For female subjects: * Pregnancy * Positive pregnancy test * No adequate contraception (e.g. sterilisation, intrauterine device (IUP), oral contraceptives) * Inability to maintain this adequate contraception during the whole study period * Lactation period Ovarian hormone substitution and oral contraception have to be continued during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Arachidonic acid induced platelet aggregation | up to day 11 (treatment 1), up to day 3 (treatment 2) |
Secondary
| Measure | Time frame |
|---|---|
| Adenosine diphosphate (ADP) Induced Platelet Aggregation | up to day 11 (treatment 1), up to day 3 (treatment 2) |
| Serum Thromboxane B2 production | up to day 11 (treatment 1), up to day 3 (treatment 2) |
| Number of patients with adverse events | up to 6 weeks |
| Collagen-induced Platelet Aggregation | up to day 11 (treatment 1), up to day 3 (treatment 2) |
| Number of patients with abnormal changes in 12-lead electrocardiogram (ECG) | Screening, 24 hours after the last Aspirin intake |
| Number of patients with clinically significant changes in vital signs | Screening, 24 hours after the last Aspirin intake |
| Assessment of tolerability on a 4-point scale | 24 hours after the last Aspirin intake |
| Number of patients with abnormal changes in laboratory parameters | up to day 11 (treatment 1), up to day 3 (treatment 2) |
Outcome results
None listed